FDA, FTC Warn CBD Retailer Rooted Apothecary On Health Claims, Unapproved Products

The Food and Drug Administration and Federal Trade Commission issued a joint warning letter Tuesday a joint warning letter to CBD seller Rooted Apothecary LLC, of Naples, Florida. 

FDA: Company Marketing To Vulnerable Customers

The company is selling unapproved CBD products online with unsupported claims that thee products can help teething and ear pain in infants, ADHD, autism, Alzheimer’s and Parkinson’s disease and other ailments, the FDA said.

"Cannabis and cannabis-derived compounds are subject to the same laws and requirements as FDA-regulated products that contain any other substance. We are working to protect Americans from companies marketing products with unsubstantiated claims that they prevent, diagnose, treat or cure a number of diseases or conditions," Acting FDA Commissioner Ned Sharpless, M.D., said in a statement.

"This is especially concerning when companies are peddling unproven CBD products for use in vulnerable populations like infants and children." 

Rooted Apothecary illegally advertised some products as dietary supplements, despite the FDA's determination that CBD products can't be advertised that way, the agency said. 

Benzinga has contacted Rooted Apothecary for comment on the FDA letter via the CBD company's website. 

No FDA-Approved Products 

Some examples of those company’s questionable claims include the following, the FDA said: 

  • "Instead of synthetic chemical[s] that can have safety concerns, this blend uses the best of nature to help calm the inflammation and pain of teething, while also promoting sleepiness for your little one."
  • "Increasing evidence suggests that CBD oil is a powerful option for pain ... anxiety ... and autism ... It seems like an attractive and safe option for children."

Not a single product sold by Rooted Apothecary was FDA-approved, the agency said. 

The FDA and FTC are requesting responses from the company within 15 working days that explain how the company plans to correct the violations.

"The FDA is working quickly to further clarify our regulatory approach for products containing cannabis and cannabis-derived compounds like CBD while using all available resources to monitor the marketplace and protect public health by taking action as needed against companies," FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., said in a statement.

Related Links:

FDA Can't Figure Out How To Regulate CBD - And It Doesn't Really Want To

3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix

Posted In: CannabisGovernmentNewsRegulationsFDAMarketsCBDRooted Apothecary
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!


Loading...